Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, September 1, 2014. To access the conference call, follow these instructions:
Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)
Passcode: 73168608 (Nektar Therapeutics is the host)In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugate technology platform. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Movantik™ (naloxegol), an investigational drug candidate, which has been filed for regulatory approvals in the U.S., Europe and Canada as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes Movantik fixed dose combination products (formerly NKTR-119), an earlier stage development program that is a co-formulation of Movantik and an opioid. NKTR-181, a novel mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatm
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  AbbVie (NYSE: ... studies in its neuroscience and oncology development programs ... th American Academy of Neurology annual meeting ... April 18-25. The accepted abstracts feature results from ... to investigational treatments in AbbVie,s pipeline. Presentations will ...
(Date:2/26/2015)... , Feb. 26, 2015  Mobility Ventures LLC, an ... with Bank of America (NYSE: BAC ) ... receive financing of the revolutionary MV-1 - - the ... the ground up to provide safe and comfortable transportation ... use their loan to purchase a new MV-1 vehicle ...
(Date:2/26/2015)... Feb. 26, 2015 Every year many millions ... fight heart disease.  Nevertheless, year after year doctors and ... as the first test to determine the status of ... pain or not, even though that technology is over ... fact that doctors know, (while most patients do not ...
Breaking Medicine Technology:AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3National Heart Health Month In February 2
(Date:2/27/2015)... Mirada, CA (PRWEB) February 27, 2015 ... patients who have suffered from injuries or diseases ... Healthpointe's team of physicians are located throughout Southern ... most-effective medical procedures to treat conditions related to ... and Dr. Edwin M. Ashley are board-certified and ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Insight ... Medical to advance the development of an in-line ... new solution is being developed in direct response ... only 73% accuracy and error margins with potentially ... error-free output measurement and provide trending data analysis ...
(Date:2/27/2015)... 2015 Dr. Christopher Saunders, a board ... at his Chadds Ford, Pa., location. The spring special ... and will be priced at $3,950 with all fees ... it will include more than $3,000 in MedSpa services ... free Dysport. , Space is very limited, so those ...
(Date:2/27/2015)... February 27, 2015 The Lymphoma Research ... exclusively to funding innovative lymphoma research and serving the ... outreach initiatives and patient services – is continuing to ... returning to the greater Miami area to host Swirl, ... Club in Miami Beach on Thursday, March 26, 2015. ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Over 440,000 patients ... be the equivalent of two jumbo jet airplanes crashing each ... to band together in an effort to do all they ... , Dr. Richard Carmona, the 17th U.S. Surgeon General, discusses ... us to be able to address safety issues to ensure ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Performing Arthroscopic Surgery Techniques for Elbow, Hand and Wrist Injuries and Diseases, such as certain Ganglion Cysts 2Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 3Health News:Lymphoma Research Foundation Returns to Miami Beach For Exclusive Swirl Wine Tasting Event 2Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2
... ... research of MRSA on board Space Shuttle Discovery. The Company is validating target ... were genetically altered to remove target genes that are believed to be associated with ... ...
... ... Dr. Brandon Colby, is the first practical book on predictive medicine and genetic testing ... the most pertinent information in an accessible, enjoyable, and easy-to-read format. , ... (PRWEB) April 6, 2010 -- ...
... PA) -- Src (short for sarcoma) is a family ... tumors, including medulloblastoma, the most common malignant cancer in ... for cancer therapy. A recent study shows that ... interfering with the cell cycle and causing cancer cell ...
... as effective as medication at preventing the formation of blood ... according to a study in the March issue of the ... "This device is as useful as blood thinners for ... superior in safety," said Douglas E. Padgett, M.D., chief of ...
... Bangsbo from the Department of Exercise and Sports Sciences, ... studies involving both men, women and children, who were ... from the studies are so remarkable that the ... are publishing a special edition issue entitled "Football for ...
... ... hour therapeutic massage. There are many other massages and spa services that customers ... ... Massage Envy’s New Jersey franchise group ( http://www.massageenvy.com/regions/NJ/Northern-New-Jersey.aspx ), a subsection of ...
Cached Medicine News:Health News:Astrogenetix Narrows in on MRSA Virulence Onboard Discovery 2Health News:Astrogenetix Narrows in on MRSA Virulence Onboard Discovery 3Health News:The Simple and Revolutionary Power to OUTSMART YOUR GENES Out April 6th -- Predictive Medicine Pioneer Dr. Brandon Colby Releases Book 2Health News:The Simple and Revolutionary Power to OUTSMART YOUR GENES Out April 6th -- Predictive Medicine Pioneer Dr. Brandon Colby Releases Book 3Health News:New pyrimidine compounds may lead to improved treatments for childhood brain cancer 2Health News:Device to revolutionize preventive blood clot care after joint replacement surgery 2Health News:Device to revolutionize preventive blood clot care after joint replacement surgery 3Health News:Scientists: Soccer improves health, fitness and social abilities 2Health News:Scientists: Soccer improves health, fitness and social abilities 3Health News:Scientists: Soccer improves health, fitness and social abilities 4Health News:Massage Envy New Jersey offers $49, 1-Hour Therapeutic Massage 2
... most comprehensive family of lightweight standard ... incision, Glaucoma filtration, and Vitreoretinal uses. ... with minimal tissue trauma and minimal ... are available in 18, 20, and ...
... Craftsmanship have produced the finest ... Ocutek now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... Craftsmanship have produced the finest ... Ocutek now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
Medicine Products: